SpectraScience Receives FDA Approval for Optical Biopsy System
MINNEAPOLIS, Minn., Nov. 20 -- SpectraScience Inc.'s pre-market approval application has been accepted by the US Food and Drug Administration. SpectraScience's optical biopsy laser system will be marketed under the name Optical Biopsy System since the FDA turned down the original name, Virtual Biopsy System, that was submitted by the company.
The system is used by physicians to help determine whether tissue in the colon is normal, pre-cancerous or cancerous without having to remove the tissue from the body. Multicenter clinical trials have demonstrated an improvement in the physician's diagnostic accuracy when the system was used, the company said.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024